Kodiak Sciences Inc (KOD) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $44.28: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10. Specifically: High short interest: 26%; Elevated put/call ratio: 3.92; Below-average business quality.
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF)... Read more
Sell if holding. Engine safety override at $44.28: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10. Specifically: High short interest: 26%; Elevated put/call ratio: 3.92; Below-average business quality. Chart setup: RSI 53 mid-range, Bollinger mid-band. Score 4.1/10, moderate confidence.
Passes 4/7 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
5 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 7.3% daily ATR makes tight stops impractical. Position-size conservatively.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $44.28: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10. Specifically: High short interest: 26%; Elevated put/call ratio: 3.92; Below-average business quality. Chart setup: RSI 53 mid-range, Bollinger mid-band. Prior stop was $41.16. Score 4.1/10, moderate confidence.
Take-profit target: $49.01 (+10.7% upside). Prior stop was $41.16. Stop-loss: $41.16.
Quality below floor (2.0 < 4.0).
Kodiak Sciences Inc trades at a P/E of N/A (forward -12.8). TrendMatrix value score: 6.0/10. Verdict: Sell.
11 analysts cover KOD with a consensus score of 4.0/5. Average price target: $56.
What does Kodiak Sciences Inc do?Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and...
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.